PRP

Combining PRP with pharmacological support during FUE hair transplantation significantly improves follicle survival, growth rates, and hair strength compared to pharmacological support alone.

PRP alone and in combination with minoxidil significantly improved hair count, density, terminal hair count, and increased the anagen ratio; the combination also significantly reduced vellus hair count and density.

Both PRP injections and microneedling significantly increased hair count and thickness after two months, with microneedling showing a greater percent increase in hair count (88.4% vs 62.4%) and PRP showing a slightly greater increase in hair thickness (58.6% vs 51.3%).

Microtrauma-based treatments like microneedling, lasers, and PRP increase hair density and thickness in androgenetic alopecia and promote regrowth in alopecia areata.

A consensus of experts identified seven recommended interventions for AGA, including oral and topical finasteride, dutasteride, and minoxidil, while identifying 17 interventions that are not recommended.

Scalp cooling is the current standard for preventing chemotherapy-induced alopecia; minoxidil, photobiomodulation, and PRP are used to promote hair regrowth, though supporting evidence varies.

Regenerative medicine showed up to 68.4% improvement in androgenetic alopecia and up to 71% improvement in vitiligo across the reviewed RCTs, indicating promising efficacy for these dermatologic disorders.

Emerging therapies such as low-level laser therapy, microneedling, platelet-rich plasma, and stem cell therapy show promise for promoting hair regrowth, while conventional treatments like minoxidil and finasteride remain effective but have limitations.

Various over-the-counter, prescription, and procedural treatments successfully promote hair growth, suggesting that a multifaceted, individualized approach is most effective.

A-PRP significantly increased hair density and hair count, with notable improvements in terminal hair density compared to baseline and control groups.

PRP shows promise for improving hair density in androgenic alopecia and provides subjective benefits in photoaging, melasma, vitiligo, and wound healing, but objective evidence is limited and heterogeneous.

PRP injections increased hair density by about 25.6 hairs/cm2 compared to saline injections over medium-term follow-up, but the evidence is low quality; benefit for alopecia areata remains uncertain.

Various treatments including 5-alpha reductase inhibitors, oral minoxidil, and PRP show efficacy, though evidence for some newer or non-pharmacological methods remains limited.

Standard treatments like topical minoxidil and oral finasteride are established, while newer modalities like PRP, LLLT, and oral minoxidil show encouraging results but lack standardized protocols.

Chemotherapy-induced alopecia affects approximately 65% of patients; current FDA-cleared prevention is limited to scalp cooling, while regrowth options include minoxidil, PBMT, and PRP.

Platelet lysate (PL) significantly improved hair regrowth compared to activated PRP and saline in hair transplant grafts, with near-complete regrowth at 4 months; PL injection alone also boosted follicular unit and hair density by 50% and 122% respectively at 7 months.

PRP contains growth factors that promote wound healing and hair follicle regeneration, showing potential for treating alopecia and improving skin condition, though efficacy varies and standardization is needed.

PRP therapy, especially when combined with minoxidil or finasteride, tends to increase hair density and count, but the magnitude of benefit varies widely due to heterogeneous preparation and treatment protocols.

The review discusses various promising topical, oral, and energy-based therapies, noting growing evidence for their efficacy in treating hair loss.

The review outlines various current and emerging therapies for hair loss, including pharmacological agents, devices, and cellular therapies.

Microneedling serves as an effective adjunct therapy for androgenic alopecia when paired with minoxidil, growth factors, or PRP, and shows promise as a standalone therapy for alopecia areata.

The review indicates that PRP can be used effectively for the treatment of hair loss, though the exact mechanism of action is not yet fully understood.

The review identifies MSC implantation, MSC-derived secretome, and PRP as promising regenerative treatment options for alopecia, though further clinical application strategies are needed.

Traditional treatments like corticosteroids and minoxidil have limited efficacy and high recurrence rates, while new strategies like JAK inhibitors and biologics are emerging.

Across 12 included trials, PRP showed a positive treatment effect in 84% of studies, with 50% demonstrating statistically significant improvement on objective measures, and consistent gains in hair density and thickness; it was reported as a safe and effective alternative to minoxidil and finasteride with few adverse effects.

Current treatments for alopecia areata lack proven long-term effectiveness for all patients and are prone to relapse. JAK-STAT inhibitors and PRP are identified as promising future therapies.

The review outlines various FDA-approved and non-FDA-approved therapies for AGA, emphasizing that treatment selection must balance efficacy, side effects, compliance, and cost.

Both non-activated and activated PRP increased hair density, with non-activated PRP showing a greater and sustained improvement over 58 weeks compared to activated PRP.

The review suggests that autologous stem cell and PRP therapies may promote hair regrowth by activating Wnt/β‑catenin signaling, prolonging the anagen phase, and reducing apoptotic signals, although specific quantitative efficacy outcomes are not reported.

PRP shows promise for promoting hair regrowth and improving skin quality, particularly when combined with microneedling or laser therapies, although standardized treatment protocols are lacking.

Finasteride and minoxidil can halt disease progression but only yield partial hair regrowth; early initiation improves outcomes, and PRP may be considered for patients unresponsive to medical therapy.

Low-level laser therapy showed superior relative effects for hair regrowth compared to other non-surgical treatments, while PRP, finasteride, minoxidil, and dutasteride demonstrated approximately equivalent mean changes in hair count.

The abstract does not provide any efficacy outcomes or quantitative results from the PRP treatment.

Hair transplant surgery is effective for creating natural-appearing hair in men, though optimal harvesting techniques and adjunctive therapies remain subjects of debate.